“ST Pharm provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the clients.” Founded in 1983, ST Pharm (formerly known as Samchully Pharmaceutical) has been offering excellent custom manufacturing services of APIs and their intermediates to meet clients’ high expectation for their use in pharmaceutical development in compliant to cGMP requirements. Our reliability in service, which is well-proven through decades of business relationship with many big pharmas and biotech clients, is the essence of our strength along with our expertise in process development and scale-up optimization. Historically, ST Pharm has been focusing our expertise on nucleoside based active pharmaceuticals in various antiviral drug applications; we became the world largest supplier of Thymidine in the late 1990s and Zidovudine in the mid 2000s and protected nucleosides in the early 2000s. ST Pharm has continuously been expanding its service offering, including synthesis of therapeutic oligonucleotides. In June 2010, ST Pharm became a subsidiary of Dong-A Pharmaceutical, the top pharmaceutical company in Korea. ST Pharm is committed to expanding its business scope into generic APIs and their intermediates with full support and collaboration with parent company Dong-A Pharmaceutical.
我们正在追踪 ST PHARM 的市场扩张
ST PHARM 的国际扩张与竞争对手的对比情况
ST PHARM你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 ST PHARM你 | 0 | 0 | — | 0 | 0 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
STPharm及其子公司Vernagen和Levatio将于3月13-14日在瑞士巴塞尔举行的RNA Leaders 2024上展示创新RNA技术。
STPharm在板桥举办2024 RISC研讨会，与全球专家分享最新RNA技术和研究。来自业界和学术界的200多名与会者参加。
STPharm在板桥举办2024年RNA创新研讨会(RISC)，约200名RNA行业和学术专家齐聚一堂，分享最新见解。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 ST PHARM 的业务、市场和增长信号的快速解答。
